BOSTON, Sept. 11, 2009 (GLOBE NEWSWIRE) -- Globalequityreport.com announces an investment report featuring biopharmaceutical company Generex Biotechnology Corp. The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Generex Biotechnology Corp. (Nasdaq:GNBT) should be of particular interest to other Biopharmaceutical companies: CPEX Pharmaceuticals Inc. (Nasdaq:CPEX); MannKind Corp. (Nasdaq:MNKD); Novo Nordisk (NYSE:NVO) and King Pharmaceuticals Inc. (NYSE:KG).
The report is available at: http://www.globalequityreport.com/gnbt
Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.
It develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines.
The company's products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy spray designed to increase energy levels for sports, work, study, travel, and overall fatigue; and GlucoBreak, a fat-free glucose spray.
Generex Biotechnology Corporation's under-development products include medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; and morphine and fentanyl products for breakthrough and postoperative pain.
The company markets its products through distributors and retail chains in Ecuador, Canada, and the United States. It has collaboration with Fertin Pharma A/S. The company was founded in 1983 and is based in Toronto, Canada.
To receive this FREE research report, visit and subscribe at: http://www.globalequityreport.com
About Globalequityreport.com
Globalequityreport.com is a leading stock web site that provides free alerts on stocks that are making big gains, as well as our weekly Newsletter, authored by The Market Timer. Globalequityreport.com also tracks small cap and hot penny stocks that we believe are on the brink of a massive upside. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on GlobalEquityReport, please visit us at http://www.globalequityreport.com
GlobalEquityReport Disclosure:
Globalequityreport.com is an independent electronic publication that provides information on selected publicly traded companies. Globalequityreport.com is not a registered investment advisor or broker dealer. Globalequityreport.com's affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.